Session Details

[O5]Oral Presentations 5

Tue. Mar 3, 2026 3:00 PM - 4:30 PM JST
Tue. Mar 3, 2026 6:00 AM - 7:30 AM UTC
Kobe Portopia Hotel(South Wing 1F Ohwada)
【R&D III】【Early-career Researchers】

[O5-01E]Pathogen specific mucosal and systemic immunity is induced by sublingual delivery of inactivated enterovirus 71

*Risa Takahashi1,2, Meito Shibuya1,2,3, Tomoyuki Yamanoue1,2, Tomonori Machita1,2, Fujimi Arai1,2, Satomi Takahashi1,2, Hiroshi Kiyono1,2,4,5,6,7, Kohtaro Fujihashi1,2,7,8,9 (1. Department of Human Mucosal Vaccinology, Chiba University Hospital (Japan), 2. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University (Japan), 3. Vaccine R&D Laboratory, Vaccine Business Division, Shionogi & Co., Ltd (Japan), 4. Future Medicine Education and Research Organization, Chiba University (Japan), 5. Department of Medicine, UC San Diego School of Medicine, San Diego (USA), 6. CU-UCSD Center for Mucosal Immunology, Allergy and Vaccines (cMAV), UC San Diego School of Medicine (USA), 7. Division of Infectious Disease Vaccine R&D, Research Institute of Disaster Medicine, Chiba University (Japan), 8. Division of Mucosal Vaccines, International Vaccince Design Center, The Institute of Medical Science, The University of Tokyo (Japan), 9. Department of Pediatric Dentistry, The University of Alabama at Birmingham (USA))
Comment()

[O5-02E]Efficacy of monovalent and bivalent Lassa virus mRNA vaccines in a surrogate mouse model

*Mei Hashizume1, Keiko Shindo1,2, Ayako Takashima1, Igor S. Lukashevich3, Juan C. de la Torre4, Masaharu Iwasaki1,2,5,6 (1. Research Institute for Microbial Diseases, The University of Osaka (Japan), 2. Center for Advanced Modalities and Drug Delivery System, The University of Osaka (Japan), 3. Department of Pharmacology and Toxicology, University of Louisville Health Sciences Center (USA), 4. Department of Immunology and Microbiology, Scripps Research (USA), 5. Center for Infectious Disease Education and Research, The University of Osaka (Japan), 6. RNA Frontier Science Division, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka (Japan))
Comment()

[O5-03E]Chikungunya: stakeholder engagement, burden estimation, and vaccine impact modelling

*Hyolim Kang1 (1. Nagasaki University (Japan))
Comment()

[O5-04E]Tailoring Nanocarriers: An Attempt to Improve the Clinical Translatability of mRNA Vaccines

*Mahmoud A. Younis1,2,3, Yusuke Sato1,2, Hideyoshi Harashima1,2 (1. Institute of Vaccine Research and Development (IVReD), Hokkaido University (Japan), 2. Faculty of Pharmaceutical Sciences, Hokkaido University (Japan), 3. Faculty of Pharmacy, Assiut University (Egypt))
Comment()

[O5-05E]Establishment of a Large Scale Metabolomics Workflow

*Shohei Asami1, Tamotsu Kato1, Yumiko Nakanishi1, Ayumi Ito1, Sayuri Sakakibara1, Hiroshi Ohno1 (1. RIKEN Center for Integrative Medical Sciences (Japan))
Comment()

[O5-06E]Developing versatile BCG-based vaccine platform against future pandemics

*HsienNeng Kao1 (1. Graduate School of medicine, Department of Immunology, Hokkaido University (Japan))
Comment()

[O5-07E]A MucoSphere-Based Oral Protein Delivery Platform for Mucosal Vaccine Applications

*Zhongwei Zhang1,2, Zhaowen Ding1,2, Shin-ichi Sawada2,3, Hiroshi Kiyono2,3,4,5, Yosuke Kurashima1,2,4,6 (1. Department of Innovative Medicine, Graduate School of Medicine, Chiba University, Chiba (Japan), 2. Chiba University Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, Chiba (Japan), 3. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba (Japan), 4. Chiba University-University of California San Diego Center for Mucosal Immunology, Allergy and Vaccine (CU-UCSD cMAV), Department of Medicine, School of Medicine,San Diego, CA (USA), 5. Division of Comparative Pathology and Medicine, Department of Pathology, University of California, San Diego, CA (USA), 6. Institute for Advanced Academic Research/ Research Institute of Disaster Medicine, Chiba University, Chiba (Japan))
Comment()

[O5-08E]A mouse model employing Salmonella Paratyphi C for the advancement of typhoid vaccine research

*Hoan Thi Pham1, Masatomo Morita2, Kohei Yamazaki3, Toshihiro Endo4, Satoshi Takayama1, Azusa Hiyoshi1, Takeshi Haneda5, Renée M. Tsolis6, Andreas J. Bäumler6, Toshio Kodama1, Hirotaka Hiyoshi1 (1. Institute of Tropical Medicine (NEKKEN), Nagasaki University (Japan), 2. National Institute of Infectious Diseases (Japan), 3. School of Veterinary Medicine, Kitasato University (Japan), 4. Phenovance LLC, Chiba (Japan), 5. School of Pharmacy, Kitasato University (Japan), 6. School of Medicine, University of California at Davis (USA))
Comment()

[O5-09E]Evolutionary Dynamics of Heparan Sulfate Utilization by SARS-CoV-2

*Shuhei Higuchi1, Hisashi Arase1,2,3,4 (1. Immunochemistry, CAMaD, Osaka University (Japan), 2. Immunochemistry, Research Institute for Microbial Diseases, Osaka University (Japan), 3. Laboratory of Immunochemistry, WPI Immunology Frontier Research Center, Osaka University (Japan), 4. Center for Infectious Disease Education and Reasearch, Osaka University (Japan))
Comment()